Skip to main content

5 Alzheimer’s Trials Set to Redefine Therapeutic Boundaries in 2025–2026

Submitted by fairsonline´s … on
5 Alzheimer’s Trials Set to Redefine Therapeutic Boundaries in 2025–2026

SHERIDAN, WYOMING – July 29, 2025 – As the Alzheimer’s treatment landscape evolves beyond legacy amyloid-targeting approaches, five upcoming trial readouts are expected to deliver pivotal data that could shift both clinical practice and market leadership. From repurposed GLP-1 drugs to precision antibody therapies, leading pharma and biotech players are advancing differentiated strategies to address persistent unmet needs in Alzheimer’s care.

Data Milestones Poised to Shape the Post-Amyloid Era

While Biogen and Eisai’s Leqembi recently became the first Alzheimer’s drug to secure full FDA approval, lingering questions around efficacy, safety, and accessibility continue to drive innovation in the space. The next wave of readouts promises to introduce more convenient delivery formats and explore entirely new biological targets, including:

  • Subcutaneous versions of existing monoclonal antibodies to improve patient adherence.
  • First-time testing of metabolic therapies in neurodegeneration.
  • Advanced antibody selectivity to mitigate amyloid-related side effects.
  • Targeted interventions for behavioral symptoms such as agitation and psychosis.

Novo Nordisk’s GLP-1 Bet Could Reshape Alzheimer’s Treatment Models

Expected in September, results from Novo Nordisk’s EVOKE and EVOKE Plus trials will assess whether semaglutide, widely prescribed for weight loss under the brand Wegovy, can slow cognitive decline in early Alzheimer’s. These studies are particularly notable for testing a metabolic therapy in a neurodegenerative context—a novel approach that aligns with mounting evidence linking insulin resistance and brain aging.

  • The trials compare semaglutide’s effects on memory and comprehension in patients with and without small vessel involvement.
  • Real-world studies have already shown semaglutide may reduce Alzheimer’s risk by 40%–70% in diabetics.
  • The readout could unlock new market potential for GLP-1s while broadening Alzheimer’s drug development pipelines.

Eli Lilly Builds on Kisunla With Advanced Anti-Amyloid Antibody

Eli Lilly is preparing for a 2026 Phase III readout for remternetug, a next-generation anti-amyloid antibody designed to offer more precise targeting and a better safety profile than its predecessor, Kisunla. Remternetug binds specifically to plaque-associated beta-amyloid precursors, and early-stage data suggest it effectively clears plaques within 85 days at high doses.

  • Interim Phase I data showed plaque clearance in 75% of high-dose patients.
  • A parallel Phase III trial (TRAILRUNNER-ALZ 3) is currently enrolling additional patients.
  • Updated FDA labeling for Kisunla, which reduces ARIA rates through dose titration, sets the stage for improved outcomes with remternetug.

Bristol Myers Squibb Eyes Expansion of Cobenfy for Alzheimer’s Psychosis

BMS is expected to report data this year from its ADEPT-2 Phase III trial evaluating Cobenfy (formerly xanomeline-trospium) in Alzheimer’s-related psychosis. The drug, already approved for schizophrenia, traces its roots to Alzheimer’s research and may finally fulfill its original therapeutic promise.

  • The trial targets 400 patients with moderate to severe Alzheimer’s psychosis.
  • Primary endpoints focus on reductions in hallucinations and delusions.
  • A positive result would mark a strategic pivot following Cobenfy’s disappointing schizophrenia outcomes.

ProMIS Neurosciences Targets Soluble Amyloid with Novel IgG1 Antibody

ProMIS’s PMN310, an investigational IgG1 antibody, is being developed to selectively neutralize misfolded amyloid-beta oligomers—structures increasingly recognized as key neurotoxic agents in Alzheimer’s pathology. Interim data from its Phase Ib PRECISE-AD trial are due in early 2026.

  • The antibody avoids binding to monomers and plaques, potentially improving tolerability.
  • Phase Ia data confirmed blood-brain barrier penetration and dose-proportional PK behavior.
  • ProMIS positions PMN310 as a “best-in-class” candidate due to its selectivity and monthly dosing potential.

Neumora Advances NMRA-511 for Alzheimer’s Agitation

By year-end, Neumora Therapeutics aims to deliver Phase Ib data for NMRA-511, a vasopressin 1a receptor antagonist targeting agitation in Alzheimer’s. The oral therapy is highly selective, which may reduce off-target effects and improve tolerability.

  • Preclinical models showed modulation of anxiety-related brain regions in primates.
  • The drug also increased frontal brain activity in healthy volunteers.
  • Following a setback with its lead depression asset, Neumora is banking on NMRA-511 to re-anchor its CNS portfolio.

Strategic Outlook: Innovation Meets Market Demand

As Alzheimer’s prevalence rises alongside an aging global population, market pressure to deliver scalable, safe, and more patient-friendly therapies is intensifying. The five readouts featured here reflect an industry in transition—from monolithic antibody strategies to multimodal, mechanistically diverse interventions. Their outcomes will influence payer decisions, reshape development pipelines, and redefine what’s possible in dementia care.

Learn more about Alzheimer’s treatment advances and clinical trials at AlzForum.org.